论文部分内容阅读
３６例先天性心脏病手术后并发迁延性腹泻患儿按２∶１随机抽样分组，治疗组２４例应用法博福－益普生制药集团所研制的思密达（Ｓｍｅｃｔａ）治疗，对照组１２例据病情应用氟哌酸或丽珠肠乐治疗，治疗组总有效率为９１％，对照组为５０％，治疗组明显优于对照组（Ｐ＜０．０１）。在缓解腹胀、改善食欲上治疗组亦优于对照组。先天性心脏病手术后多种因素可引起肠粘膜屏障损伤，为致腹泻的重要病因。思密达修复及保护肠粘膜屏障的功能是治愈迁延性腹泻的基础。
Thirty-six children with persistent diarrhea complicated with congenital heart disease were randomly divided into 2 groups according to a 2: 1 ratio. 24 cases in the treatment group were treated with Smecta developed by Fabrofen-Ipsen Pharmaceutical Group and 12 in control group Cases according to the disease application of norfloxacin or Lizhu intestinal music treatment, the total effective rate was 91% in the control group, the control group was 50%, the treatment group was significantly better than the control group (P <0.01). In relieve bloating, improve appetite on the treatment group also better than the control group. Various factors after congenital heart disease can cause intestinal mucosal barrier injury, diarrhea is an important cause. Smectite repair and protection of intestinal mucosal barrier function is the basis for the treatment of persistent diarrhea.